Trane (TT) Q2 EPS Up 18 Revenue Up 8
Adjusted earnings per share (non-GAAP) surpassed estimates at $3.88, compared to the expected $3.79, representing an 18% increase from Q2 2024.
GAAP revenue climbed 8% to $5.75 billion, but missed expectations by 0.47%. Americas Commercial HVAC led growth.
Full-year 2025 guidance was raised, with adjusted EPS targeted at $13.05 and organic revenue growth expected to reach 8%.
These 10 stocks could mint the next wave of millionaires ›
Trane Technologies Plc (NYSE:TT), a leader in heating, ventilation, air conditioning (HVAC), and refrigeration solutions, delivered its second quarter 2025 results on July 30, 2025. The earnings release highlighted adjusted earnings per share (EPS) of $3.88, beating analyst estimates of $3.79 and marking an 18 % rise from the prior year. Revenue (GAAP) grew 8% to $5.75 billion, slightly under the $5.77 billion GAAP consensus estimate. Overall, the quarter reflected ongoing strength in the Americas, particularly from Commercial HVAC, while management lifted its guidance for the full fiscal year.
Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change
EPS (Non-GAAP) $3.88 $3.79 $3.30 18%
Revenue (GAAP) $5.75 billion $5.77 billion $5.31 billion 8%
Adjusted Operating Margin 20.3% 19.4% 0.9 pp
Adjusted EBITDA $1.25 billion $1.12 billion 12%
Free Cash Flow (Non-GAAP) $841 million1 $810 million1 3.8%
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Understanding Trane Technologies Plc's Business
Trane Technologies Plc designs, manufactures, and services climate-control solutions for commercial, residential, and transport applications worldwide. Its brands include Trane for HVAC systems and Thermo King for transport refrigeration units and trailer cooling. Products range from large-scale commercial HVAC equipment to advanced residential air conditioners and rental solutions.
The company is actively focused on sustainability, recurring revenue through long-term service agreements, and innovation in energy-efficient products. It's recognized for its 'Gigaton Challenge' to reduce customer greenhouse gas emissions, a goal that has become central to its brand and competitive positioning. Key business metrics are influenced by regional performance, strong service segment results, and the ability to manage global supply chains amid regulatory and tariff shifts.
Quarter Highlights: Growth in Americas Offsets Global Softness
The standout was continued momentum in the Americas, particularly in Commercial HVAC systems. Bookings for the segment reached $4.54 billion, an 8% increase from last year, and net revenue grew 9% year-over-year. Operating margin in the Americas expanded to 22.4%, reflecting both strong pricing and operational productivity. Management noted that 'Bookings strength led by Americas Commercial HVAC applied solutions up over 60 percent.'
By contrast, performance outside the Americas was mixed. In the Europe, Middle East, and Africa (EMEA) segment, bookings were up just 5%, and organic bookings declined 2%. Margins in EMEA narrowed, with the adjusted operating margin falling to 17.3% due to heavy reinvestment and inflation. The Asia Pacific segment saw bookings drop 16% and revenue slip 7%, weighed down by weaker demand in China and lower volumes overall. Despite these headwinds, Trane highlighted that high-value, service-oriented business lines remain stable, offering some buffer against changes in equipment sales.
The company's global backlog was $7.1 billion at June 30, 2025, a 6% increase from year-end, but sequentially decreased by about $125 million. This drop reflected softness in the Residential and Transport businesses, even as Commercial HVAC backlog remained elevated.
With 'bespoke applied solutions' cited as a major driver for growth, operationally, positive pricing actions and productivity gains offset most inflationary pressures. Adjusted operating margin was 20.3%, up 0.9 percentage points from Q2 2024. However, management flagged tariffs as a possible risk, estimating an annual $250–275 million cost, to be covered 'dollar for dollar' through pricing and cost-saving efforts.
On capital allocation, Trane spent approximately $1.8 billion year-to-date through July, covering dividend payments ($420 million), acquisitions ($275 million), share buybacks ($1 billion), and debt reduction ($150 million) year-to-date through July. Free cash flow (non-GAAP) for the six months ended June 30 was $841 million, a 3.8% improvement over the previous year. Cash and debt balances reflected this activity: cash on hand at quarter end was $774 million (down from $1,326 million a year ago), while debt was reduced to $4.62 billion.
The quarterly dividend was raised 12% earlier in the year, effective with the Q1 payment, continuing a multi-year trend of dividend increases.
Looking Ahead: Guidance and Investor Focus
For FY2025, management increased its outlook, now targeting organic revenue growth of 8% and adjusted EPS of approximately $13.05. The company attributed this confidence to record backlog, resilient pricing, and sustained demand in Commercial HVAC. Management also noted that additional price increases to offset tariffs could provide upside to revenue guidance for the full year, though these are not yet included in official targets as cost and price actions are monitored across key markets.
Going forward, areas for investors to watch include the pace at which backlog is converted to revenue, progress in international markets, and any developments in tariff rules or supply chain costs. Residential and Transport remain more volatile, with softer bookings this quarter, Service businesses are expected to provide stability. The company's continued focus on sustainability, innovation, and service offerings is expected to remain central in its strategy as it moves through the rest of the year.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 182% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of July 29, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 minutes ago
- Cision Canada
Automated Logic Completes Acquisition of Control Solutions, Ltd. Establishing First Field Office in British Columbia
KENNESAW, Ga., Aug. 1, 2025 /CNW/ -- Automated Logic – Canada, Ltd. (ALC), a leading provider of innovative building-management solutions and a part of Carrier Global Corporation (NYSE: CARR), global leader in intelligent climate and energy solutions, today announced that it has acquired Control Solutions, Ltd. (CSL), an independent provider of integrated building-automation systems headquartered in Coquitlam, British Columbia. The transaction establishes ALC's first company-owned controls field office in Vancouver, significantly expanding its intelligent building-automation footprint in Western Canada. "This acquisition represents a strategic step in strengthening Automated Logic's presence in Canada and expanding our ability to deliver integrated, intelligent building solutions in high-growth sectors across British Columbia," said Andy Bierer, Managing Director, ALC Field. Control Solutions, Ltd. designs, installs and services building automation systems for complex facilities across commercial real estate, education, data centers, residential and large mixed-use developments. The company's 100-plus employees deliver advanced building automation and control solutions, retrofit upgrades and multi-year service contracts that help customers optimize energy performance and operational resilience. "Joining Automated Logic is an exciting new chapter for our team," said Chad Thomas, President, Control Solutions, Ltd. and Eddie McCool, CEO, Control Solutions, Ltd. "ALC's leadership in intelligent building technologies and our shared commitment to innovation and quality will allow us to deliver even greater value to our customers throughout British Columbia and beyond." CSL's existing leadership and employees will remain in place, continuing to serve customers from their Coquitlam office and project sites across the province. Terms of the transaction were not disclosed. For more information, visit or follow Automated Logic on LinkedIn. About Automated Logic Corporation Automated Logic Corporation provides innovative building-management solutions that maximize energy efficiency and sustainable building operation while ensuring comfort. Its intuitive products control and monitor building functions such as heating, air conditioning and lighting for commercial office, education, health care, government and data center markets through a global network of independent dealers and field offices. Automated Logic is a part of Carrier Global Corporation, global leader in intelligent climate and energy solutions. For more information, visit or follow Automated Logic on LinkedIn.
Globe and Mail
2 minutes ago
- Globe and Mail
Trump demands official overseeing jobs data be fired after dismal employment report
WASHINGTON (AP) — President Donald Trump on Friday called for the firing of the head of the agency that produces the monthly jobs figures after a report showed hiring slowed in July and was much weaker in May and June than previously reported. Trump in a post on his social media platform alleged that the figures were manipulated for political reasons and said that Erika McEntarfer, the director of the Bureau of Labor Statistics, who was appointed by former President Joe Biden, should be fired. 'I have directed my Team to fire this Biden Political Appointee, IMMEDIATELY,' Trump said on Truth Social. 'She will be replaced with someone much more competent and qualified.' Friday's jobs report showed that just 73,000 jobs were added last month and that 258,000 fewer jobs were created in May and June than previously estimated. McEntarfer was nominated by Biden in 2023 and became the Commissioner of the Bureau of Labor Statistics in January 2024. Commissioners typically serve four-year terms but since they are political appointees can be fired. The commissioner is the only political appointee of the agency, which has hundreds of career civil servants. Trump focused much of his ire on the revisions the agency made to previous hiring data. Job gains in May were revised down to just 19,000 from 125,000, and in June they were cut to 14,000 from 147,000. In July, only 73,000 positions were added. The unemployment rate ticked up to a still-low 4.2% from 4.1%. 'No one can be that wrong? We need accurate Jobs Numbers,' Trump wrote. 'She will be replaced with someone much more competent and qualified. Important numbers like this must be fair and accurate, they can't be manipulated for political purposes.' The monthly employment report is one of the most closely-watched pieces of government economic data and can cause sharp swings in financial markets. The disappointing figure sent U.S. market indexes about 1.5% lower Friday. While the jobs numbers are often the subject of political spin, economists and Wall Street investors — with millions of dollars at stake — have always accepted U.S. government economic data as free from political manipulation.
Globe and Mail
2 minutes ago
- Globe and Mail
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.99. In the year-ago period, the company had reported a loss of $3.33. Total revenues in the quarter were $142 million, which beat the Zacks Consensus Estimate of $127 million. Revenues declined by around 41% year over year, owing to lower net product sales. More on MRNA's Q2 Earnings Moderna currently has two marketed vaccines in its portfolio, the COVID-19 vaccine Spikevax and the recently launched RSV vaccine mResvia. Product sales were down 38% year over year to $114 million due to lower Spikevax sales. Per Moderna, almost the entirety of this number was generated from Spikevax, with a 'negligible' contribution from mResvia. Moderna generated $28 million from grants, collaborations, licensing and royalty revenues in the quarter, down 51% year over year. The company usually earns collaboration revenues from agreements with several big pharma/biotech companies, including Merck MRK and Vertex Pharmaceuticals. Operating Costs Decline Amid Streamlining Efforts Selling, general and administrative (SG&A) expenses were $230 million, down 14% year over year. This downside was primarily due to broad-based cost-cutting activities. Research & development (R&D) expenses were down 43% to $700 million, driven by the reduction in clinical spending across respiratory programs due to the timing of clinical studies and program wind-downs. MRNA Revises '25 Outlook Moderna revised its total revenue guidance for the full year, which was initially issued in January. It now expects total revenues in the range of $1.5-$2.2 billion, which reflects a $300 million cut from the upper end of the previous guidance of $1.5-$2.5 billion. Per the company, this revision is mainly driven by the timing shift of deliveries of contracted revenue for the U.K. into the first quarter of 2026. Shares of Moderna were down 6% in pre-market trading today, attributed to the downgrade in guidance. Year to date, the stock has underperformed the industry. Owing to the seasonality of its respiratory business, Moderna is expected to generate the majority of the guided revenue in the second half of the year. The company has already recorded total revenues worth $250 million in the first half of 2025. For the second half, Moderna expects a revenue split of 40-50% in the third quarter, with the balance in the fourth quarter. MRNA also lowered the guidance for R&D expenses during the quarter, now expecting to incur between $3.6 billion and $3.8 billion (previous guidance: $4.1 billion). This is likely to be due to the company's plans to cut nearly 10% workforce, as announced yesterday. Moderna reiterated its projections for SG&A expenses to be around $1.1 billion. The company also lowered its forecasts for capital expenditure to be about $0.3 billion (previous guidance: $0.4 billion). Moderna expects to end 2025 with cash, cash equivalents and investments of nearly $6 billion. MRNA's Recent Pipeline Updates The company secured three regulatory approvals from the FDA in the past few months. These include label expansion for using mResvia in high-risk adults aged 18-59 and full approval for Spikevax in pediatric patients aged between six months through 11 years old (previously granted emergency use authorization for this population by the agency). The FDA also approved mNexspike, a next-generation refrigerator-stable version of Spikevax. Moderna is also evaluating several pipeline candidates in late-stage development. Last month, the company reported that a phase III efficacy study (P304) showed that its influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy to an approved flu shot marketed by GSK. The above results not only supports potential approval of the standalone flu shot but also strengthen the case for refiling mRNA-1083, an investigational combination vaccine against COVID-19 and influenza. In May, Moderna voluntarily withdrew a filing with the FDA for mRNA-1083 after the agency requested additional efficacy data for the flu component. This candidate integrates the company's COVID-19 shot with mRNA-1010. Moderna is currently in discussions with the FDA regarding data requirements for resubmitting the regulatory filing. An important candidate in the company's pipeline is intismeran autogene, a personalized cancer therapy, which is being developed in collaboration with Merck. The companies are evaluating the therapy in three pivotal phase III studies, one in the melanoma indication and the other two in the non-small cell lung cancer space. It is also being evaluated in separate mid-stage studies for high-risk bladder cancers (both muscle-invasive and non-muscle-invasive) and adjuvant renal cell carcinoma. Moderna and Merck recently launched a new phase II study evaluating the therapy as a first-line treatment for patients with metastatic melanoma. In a separate press release, Moderna announced that the U.K. Court of Appeal has upheld the validity of its EP'949 patent and infringement by Pfizer PFE / BioNTech 's BNTX COVID-19 vaccine Comirnaty. The patent relates to chemically modified mRNA, one of the company's foundational technologies that enables the development of mRNA-based medicines. The latest decision affirms the High Court's initial ruling from last year, which was also in Moderna's favor. MRNA's Zacks Rank Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
